Among different clinical trials, both GLP-1RAs and GLP-1/GIP dual agonists are showing positive effects in reducing liver fat content and reversion of MASH [12, 38]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.